FDA approval of copper histidinate (Zycubo) for Menkes disease: a therapeutic breakthrough in a rare pediatric neurodegenerative disorder.

Menkes disease (MD) is a rare X-linked recessive disorder caused by mutations in the ATP7A gene, leading to impaired copper transport and deficiency of essential copper-dependent enzymes. The disease is characterized by progressive neurodegeneration, refractory seizures, hypotonia, and connective tissue abnormalities, typically presenting within the first months of life. Without effective treatment, the prognosis remains poor, with most affected children dying before 3 years of age. Traditional therapeutic strategies have included oral copper salts; however, these approaches have shown limited clinical efficacy due to inadequate correction of systemic and cerebral copper deficiency. Parenteral copper histidinate therapy represented a significant advancement by improving copper bioavailability and enhancing systemic absorption. Early initiation of therapy, particularly within the first month of life, has been associated with improved survival and better neurodevelopmental outcomes in some patients. Recently, the U.S. Food and Drug Administration approved Zycubo (copper histidinate) as the first disease-specific treatment for children with MD, marking an important milestone in the management of this rare condition. Despite its clinical benefits, treatment may be associated with adverse effects including infections, respiratory complications, anemia, and injection-site reactions, necessitating careful monitoring during therapy. Continued research is required to evaluate long-term safety, optimize therapeutic strategies, and further improve outcomes for affected children.